Porosome Therapeutics
Boston, US · Founded 2021 · Delaware corporation
Founders & leadership
GM
Guillermo MarmolExecutive
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 2 rounds · 2022–2023
▶$3.6MraisedMar 2026 · 7 investors · BiotechnologyRule 506(b)
▶$3.6MraisedMar 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guillermo MarmolExecutive Officer
- Amount sold
- $3.6M
- Minimum investment
- $50K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$305KraisedJun 2022 · 3 investors · BiotechnologyRule 506(b)
▶$305KraisedJun 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guillermo MarmolExecutive Officer
- Amount sold
- $305K
- Minimum investment
- $50K
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Porosome Therapeutics raised?
- Porosome Therapeutics has disclosed $3.9M raised across 2 rounds.
- Where is Porosome Therapeutics headquartered?
- Porosome Therapeutics is headquartered in Boston, US.